Compare Stocks: RCKT, ANAB, FBRX, and BCAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$56.80 -1.1%	$58.18	$11.40 ▼ $72.36	$1.68B	0.71	388,542 shs	1.06 million shs
BCAX Bicara Therapeutics	$23.17 -0.7%	$26.48	$10.30 ▼ $30.99	$1.53B	-0.82	598,424 shs	296,877 shs
FBRX Forte Biosciences	$76.99	$60.99	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
RCKT Rocket Pharmaceuticals	$3.86 +1.8%	$3.57	$2.53 ▼ $5.45	$423.73M	0.5	1.37 million shs	888,519 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	+0.92%	+3.71%	+12.77%	+152.11%
BCAX Bicara Therapeutics	0.00%	-1.11%	-15.78%	+15.85%	+93.08%
FBRX Forte Biosciences	0.00%	0.00%	+0.21%	+366.04%	+595.48%
RCKT Rocket Pharmaceuticals	0.00%	0.00%	+9.04%	+40.36%	+16.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$56.80 -1.1%	$58.18	$11.40 ▼ $72.36	$1.68B	0.71	388,542 shs	1.06 million shs
BCAX Bicara Therapeutics	$23.17 -0.7%	$26.48	$10.30 ▼ $30.99	$1.53B	-0.82	598,424 shs	296,877 shs
FBRX Forte Biosciences	$76.99	$60.99	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
RCKT Rocket Pharmaceuticals	$3.86 +1.8%	$3.57	$2.53 ▼ $5.45	$423.73M	0.5	1.37 million shs	888,519 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	+0.92%	+3.71%	+12.77%	+152.11%
BCAX Bicara Therapeutics	0.00%	-1.11%	-15.78%	+15.85%	+93.08%
FBRX Forte Biosciences	0.00%	0.00%	+0.21%	+366.04%	+595.48%
RCKT Rocket Pharmaceuticals	0.00%	0.00%	+9.04%	+40.36%	+16.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.67	Moderate Buy	$79.85	40.57% Upside
BCAX Bicara Therapeutics	2.80	Moderate Buy	$32.64	40.86% Upside
FBRX Forte Biosciences	2.00	Hold	$71.67	-6.91% Downside
RCKT Rocket Pharmaceuticals	2.30	Hold	$8.57	122.06% Upside

Current Analyst Ratings Breakdown

Latest RCKT, ANAB, FBRX, and BCAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/31/2026	ANAB AnaptysBio	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$78.00
8/25/2026	ANAB AnaptysBio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$75.00 ➝ $70.00
8/25/2026	ANAB AnaptysBio	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold	$70.00
8/24/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
8/21/2026	BCAX Bicara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $33.00
8/12/2026	BCAX Bicara Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	7.17	N/A	N/A	$1.34 per share	42.39
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.08 per share	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.66 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.36 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	-$1.08	N/A	19.12	N/A	-11.53%	N/A	-7.75%	9/9/2026 (Estimated)
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	11/13/2026 (Estimated)
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	11/5/2026 (Estimated)

Latest RCKT, ANAB, FBRX, and BCAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q2 2026	ANAB AnaptysBio	-$0.4133	N/A	N/A	N/A	$6.67 million	N/A
8/12/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
BCAX Bicara Therapeutics	N/A	11.59	11.59
FBRX Forte Biosciences	N/A	10.01	10.01
RCKT Rocket Pharmaceuticals	0.05	9.24	9.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
BCAX Bicara Therapeutics	N/A
FBRX Forte Biosciences	77.63%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
BCAX Bicara Therapeutics	13.80%
FBRX Forte Biosciences	4.40%
RCKT Rocket Pharmaceuticals	21.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.61 million	20.28 million	Optionable
BCAX Bicara Therapeutics	32	66.17 million	57.04 million	N/A
FBRX Forte Biosciences	5	21.23 million	20.30 million	Optionable
RCKT Rocket Pharmaceuticals	240	109.78 million	86.39 million	Optionable

RCKT, ANAB, FBRX, and BCAX Headlines

Recent News About These Companies

Rocket Pharmaceuticals (NASDAQ:RCKT) Coverage Initiated at Chardan Capital

September 3 at 1:18 AM | americanbankingnews.com

BlackRock Inc. Invests $33.94 Million in Rocket Pharmaceuticals, Inc. $RCKT

September 2, 2026 | marketbeat.com

Chardan Capital Reiterates "Buy" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

September 1, 2026 | marketbeat.com

Ieq Capital LLC Invests $1.51 Million in Rocket Pharmaceuticals, Inc. $RCKT

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Rocket Pharmaceuticals, Inc. $RCKT

August 26, 2026 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts

August 21, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells 3,493 Shares of Stock

August 18, 2026 | insidertrades.com

Rocket Pharmaceuticals' General Counsel Martin Wilson Sells Shares to Cover RSU Tax Obligations

August 17, 2026 | kalkinemedia.comK

Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells $11,806.34 in Stock

August 17, 2026 | marketbeat.com

Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT

August 17, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating

August 17, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells 4,701 Shares

August 14, 2026 | insidertrades.com

Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock

August 13, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) COO Christopher James Stevens Sells 36,658 Shares of Stock

August 13, 2026 | marketbeat.com

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

August 11, 2026 | zacks.com

Wedbush Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price

August 11, 2026 | marketbeat.com

Rocket Pharmaceuticals: Q2 Earnings Snapshot

August 11, 2026 | aol.comA

Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results, Beats Estimates By $0.22 EPS

August 10, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Rating Lowered to Sell at Wall Street Zen

August 9, 2026 | marketbeat.com

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

August 3, 2026 | benzinga.com

Rocket Pharmaceuticals: Can The AAV9 Cardiovascular Pipeline Justify The Current Valuation?

July 29, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, ANAB, FBRX, and BCAX Company Descriptions

AnaptysBio NASDAQ:ANAB

$56.80 -0.66 (-1.15%)

As of 09/4/2026 04:00 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Bicara Therapeutics NASDAQ:BCAX

$23.17 -0.17 (-0.73%)

As of 09/4/2026 04:00 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Forte Biosciences NASDAQ:FBRX

$76.99 0.00 (0.00%)

As of 08/27/2026

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.86 +0.07 (+1.85%)

As of 09/4/2026 04:00 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCKT, ANAB, FBRX, and BCAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCKT, ANAB, FBRX, and BCAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCKT, ANAB, FBRX, and BCAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, ANAB, FBRX, and BCAX Company Descriptions

AnaptysBio NASDAQ:ANAB

Bicara Therapeutics NASDAQ:BCAX

Forte Biosciences NASDAQ:FBRX

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCKT, ANAB, FBRX, and BCAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCKT, ANAB, FBRX, and BCAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCKT, ANAB, FBRX, and BCAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, ANAB, FBRX, and BCAX Company Descriptions

AnaptysBio NASDAQ:ANAB

Bicara Therapeutics NASDAQ:BCAX

Forte Biosciences NASDAQ:FBRX

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools